A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma

Amber K. Weiner,Alexander B. Radaoui,Matthew Tsang,Daniel Martinez,Simone Sidoli,Karina L. Conkrite,Alberto Delaidelli,Apexa Modi,Jo Lynne Rokita,Khushbu Patel,Maria V. Lane,Bo Zhang,Chuwei Zhong,Brian Ennis,Daniel P. Miller,Miguel A. Brown,Komal S. Rathi,Pichai Raman,Jennifer Pogoriler,Tricia Bhatti,Bruce Pawel,Tina Glisovic-Aplenc,Beverly Teicher,Stephen W. Erickson,Eric J. Earley,Kristopher R. Bosse,Poul H. Sorensen,Kateryna Krytska,Yael P. Mosse,Karin E. Havenith,Francesca Zammarchi,Patrick H. van Berkel,Malcolm A. Smith,Benjamin A. Garcia,John M. Maris,Sharon J. Diskin
DOI: https://doi.org/10.1101/2023.12.06.570390
2024-01-07
Abstract:Cancer immunotherapies have produced remarkable results in B-cell malignancies; however, optimal cell surface targets for many solid cancers remain elusive. Here, we present an integrative proteomic, transcriptomic, and epigenomic analysis of tumor specimens along with normal tissues to identify biologically relevant cell surface proteins that can serve as immunotherapeutic targets for neuroblastoma, an often-fatal childhood cancer of the developing nervous system. We apply this approach to human-derived cell lines (N=9) and cell/patient-derived xenograft (N=12) models of neuroblastoma. Plasma membrane-enriched mass spectrometry identified 1,461 cell surface proteins in cell lines and 1,401 in xenograft models, respectively. Additional proteogenomic analyses revealed 60 high-confidence candidate immunotherapeutic targets and we prioritized Delta-like canonical notch ligand 1 (DLK1) for further study. High expression of DLK1 directly correlated with the presence of a super-enhancer spanning the DLK1 locus. Robust cell surface expression of DLK1 was validated by immunofluorescence, flow cytometry, and immunohistochemistry. Short hairpin RNA mediated silencing of DLK1 in neuroblastoma cells resulted in increased cellular differentiation. ADCT-701, a DLK1-targeting antibody-drug conjugate (ADC), showed potent and specific cytotoxicity in DLK1-expressing neuroblastoma xenograft models. Moreover, DLK1 is highly expressed in several adult cancer types, including adrenocortical carcinoma (ACC), pheochromocytoma/paraganglioma (PCPG), hepatoblastoma, and small cell lung cancer (SCLC), suggesting potential clinical benefit beyond neuroblastoma. Taken together, our study demonstrates the utility of comprehensive cancer surfaceome characterization and credentials DLK1 as an immunotherapeutic target.
Cancer Biology
What problem does this paper attempt to address?
The main issue this paper attempts to address is finding effective immunotherapy targets for neuroblastoma. Specifically, the researchers identified highly expressed proteins on the surface of neuroblastoma cells by integrating proteomics, transcriptomics, and epigenomics data, and screened for candidate targets with potential immunotherapeutic value. Ultimately, they identified Delta-like canonical notch ligand 1 (DLK1) as a priority immunotherapy target for further study. ### Main Issues: 1. **Finding effective immunotherapy targets**: Neuroblastoma is a highly lethal pediatric cancer with limited current treatment options. The researchers aim to find new immunotherapy targets through a systematic approach to improve treatment outcomes. 2. **Validating the therapeutic potential of DLK1**: The researchers not only identified DLK1 as a potential target but also validated its expression in neuroblastoma and its feasibility as an immunotherapy target through various experimental methods. ### Research Methods: - **Proteomics analysis**: Mass spectrometry was used to identify highly expressed proteins on the surface of neuroblastoma cell lines and patient-derived xenograft models. - **Multi-omics data integration**: By combining proteomics, transcriptomics, and epigenomics data, proteins that are lowly expressed in normal tissues but highly expressed in neuroblastoma were screened. - **Functional validation**: The expression of DLK1 on the surface of neuroblastoma cells was validated using RNA interference, immunofluorescence, flow cytometry, and immunohistochemistry. - **Drug testing**: The anti-tumor activity of an antibody-drug conjugate targeting DLK1 (ADCT-701) was tested in neuroblastoma xenograft models. ### Main Findings: - **High expression of DLK1**: DLK1 is highly expressed in neuroblastoma and its expression is associated with super-enhancers. - **Function of DLK1**: Knockdown of DLK1 promoted differentiation of neuroblastoma cells, indicating its role in maintaining the undifferentiated state of the cells. - **Efficacy of ADCT-701**: ADCT-701 showed significant anti-tumor activity in DLK1-high neuroblastoma xenograft models with no apparent toxicity. In summary, this study successfully identified and validated DLK1 as a potential immunotherapy target for neuroblastoma through systematic multi-omics analysis, providing an important basis for developing new therapeutic strategies.